💡NEW—Vaccine efficacy 91% of 2 Pfizer shots protecting against pediatric multi system inflammatory syndrome (MIS-C) in teens age 12-18. 📌Huge—this was a major severe outcome of #COVID19 in kids before. This is a reminder kids need 2 shots. #GetVaccinated cdc.gov/mmwr/volumes/7… 
2) What is already known about this topic?
Vaccine effectiveness against multisystem inflammatory syndrome in children (MIS-C), which can occur 2–6 weeks after SARS-CoV-2 infection, has remained uncharacterized.
Vaccine effectiveness against multisystem inflammatory syndrome in children (MIS-C), which can occur 2–6 weeks after SARS-CoV-2 infection, has remained uncharacterized.
3) What is added by this report?
Estimated effectiveness of 2 doses of Pfizer-BioNTech vaccine against MIS-C was 91% (95% CI = 78%–97%). Among critically ill MIS-C case-patients requiring life support, all were unvaccinated.
Estimated effectiveness of 2 doses of Pfizer-BioNTech vaccine against MIS-C was 91% (95% CI = 78%–97%). Among critically ill MIS-C case-patients requiring life support, all were unvaccinated.
4) What are the implications for public health practice?
Receipt of 2 doses of Pfizer-BioNTech vaccine is highly effective in preventing MIS-C in persons aged 12–18 years. These findings further reinforce the COVID-19 vaccination recommendation for eligible children.
Receipt of 2 doses of Pfizer-BioNTech vaccine is highly effective in preventing MIS-C in persons aged 12–18 years. These findings further reinforce the COVID-19 vaccination recommendation for eligible children.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
